The PEXIVAS clinical trial demonstrated that, in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV), adjuvant plasma exchange did not reduce the risk of all-cause mortality or end-stage kidney disease and a reduced dose of glucocorticoids was not inferior to standard dosing. These findings might warrant a change in standard AAV therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Robson, J. et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology 54, 471–481 (2015).
Walsh, M. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. 382, 622–631 (2020).
Xiao, H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955–963 (2002).
Jayne, D. R. W. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180–2188 (2007).
Walsh, M. et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 84, 397–402 (2013).
Walsh, M. et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am. J. Kidney Dis. 57, 566–574 (2011).
Kidney Disease Improving Global Outcomes. KDIGO Clinical practice guideline for glomerulonephritis. Kidnet Int. Suppl. 2, 1–274 (2012).
Weiner, M. et al. Effect of treatment on damage and hospitalization in elderly patients with microscopic polyangiitis and granulomatosis with polyangiitis. J. Rheumatol. https://doi.org/10.3899/jrheum.190019 (2019).
de Lind van Wijngaarden, R. A. et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J. Am. Soc. Nephrol. 17, 2264–2274 (2006).
Walsh, M., Merkel, P., Mahr, A. & Jayne, D. The effects of duration of glucocorticoid therapy on relapse rate in anti-neutrophil cytoplasm antibody associated vasculitis: a meta-analysis. Arthritis Care 62, 1166–1173 (2011).
Acknowledgements
D.G. is supported by a Cupid Discovery grant and Gorski funds.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.G. acts as a consultant for ChemoCentryx and Aurinia. A.M. declares no competing interests.
Rights and permissions
About this article
Cite this article
Morris, A., Geetha, D. PEXIVAS challenges current ANCA-associated vasculitis therapy. Nat Rev Nephrol 16, 373–374 (2020). https://doi.org/10.1038/s41581-020-0269-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-020-0269-6
This article is cited by
-
Novel Therapies for ANCA-associated Vasculitis
Current Rheumatology Reports (2021)
